These preclinical results prompted a non-randomized, open-label Phase I/II clinical trial which began in 2019 and plans to enroll 75 patients with either low-grade glioma (LGG) or HGG investigating co-administration of hydroxychloroquine, dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor [98]. Here, BRAF is linked to low grade glioma.